Veracyte (NASDAQ: VCYT) reported Q3 EPS of $0.33, $0.30 better than the analyst estimate of $0.03. Revenue for the quarter came in at $115.9 million versus the consensus estimate of $109.85 million.

GUIDANCE:

Veracyte sees FY2024 revenue of $442-445 million, versus the consensus of $436.3 million. In addition, the company now expects cash, cash equivalents and short-term investments at the end of the year to be $280 million to $285 million compared to prior guidance of $260 million to $270 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.